复发胶质母细胞瘤的再程放疗:残余肿瘤体积的意义
本研究分析了2009年1月至2019年6月在埃尔朗根-纽伦堡大学接受再程放疗的71例复发CNS WHO 4级IDH野生型胶质母细胞瘤患者,中位随访73.8个月后中位总生存期9.6个月、中位无进展生存期5.3个月,多因素分析显示再程放疗时残余强化肿瘤体积是总生存期的唯一主要预测因素(每cm³ HR 1.040,p<0.001)。
要点
- 再程放疗时残余强化肿瘤体积是复发胶质母细胞瘤总生存期的唯一主要预测因素(每cm³ HR 1.040,p<0.001)。
- 94.4%患者按计划完成再程放疗,中位总生存期9.6个月,中位无进展生存期5.3个月。
- 常规分割再程放疗联合替莫唑胺(49.3%)或洛莫司汀(12.7%)是可行的治疗方案。
核心结论
- 常规分割再程放疗是复发高级别胶质瘤可行且有效的治疗。
- 残余肿瘤体积的显著预后影响凸显了将最大安全切除与再程放疗相结合以改善结局的重要性。
研究设计与样本
- 研究分析了2009年1月至2019年6月在埃尔朗根-纽伦堡大学接受再程放疗的71例复发CNS WHO 4级IDH野生型胶质母细胞瘤患者。
- 每3个月进行影像学随访,采用RANO标准定义无进展生存期。
- 使用深度学习自动分割流程并经专家验证测量强化肿瘤体积,并与临床和分子病理因素联合评估。
主要发现
- 大多数患者接受常规分割再程放疗(84.5%),剂量为45 Gy分1.8 Gy每次,联合替莫唑胺(49.3%)或洛莫司汀(12.7%)。
- 94.4%的患者按计划完成再程放疗。
- 中位随访73.8个月后,88.7%的患者死亡。
- 中位总生存期为9.6个月,中位无进展生存期为5.3个月。
- 多因素分析确定再程放疗时残余强化肿瘤体积(每cm³ HR 1.040,p<0.001)是总生存期的唯一主要预测因素。
临床怎么用
- 作者认为常规分割再程放疗是复发高级别胶质瘤可行且有效的治疗。
- 作者认为残余肿瘤体积的显著预后影响凸显了将最大安全切除与再程放疗相结合以改善结局的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrent glioblastoma has a poor prognosis, and its optimal management remains unclear. Reirradiation (re-RT) is a promising treatment option, but long-term outcomes and optimal patient selection criteria are not well established. METHODS: This study analyzed 71 patients with recurrent CNS WHO grade 4, IDHwt glioblastoma (GBM) who underwent re-RT at the University of Erlangen-Nuremberg between January 2009 and June 2019. Imaging follow-ups were conducted every 3 months. Progression-free survival (PFS) was defined using RANO criteria. Outcomes, feasibility, and toxicity of re-RT were evaluated. Contrast-enhancing tumor volume was measured using a deep learning auto-segmentation pipeline with expert validation and jointly evaluated with clinical and molecular-pathologic factors. RESULTS: Most patients were prescribed conventionally fractionated re-RT (84.5%) with 45 Gy in 1.8 Gy fractions, combined with temozolomide (TMZ, 49.3%) or lomustine (CCNU, 12.7%). Re-RT was completed as planned in 94.4% of patients. After a median follow-up of 73.8 months, 88.7% of patients had died. The median overall survival was 9.6 months, and the median progression-free survival was 5.3 months. Multivariate analysis identified residual contrast-enhancing tumor volume at re-RT (HR 1.040 per cm3, p < 0.001) as the single dominant predictor of overall survival. CONCLUSION: Conventional fractionated re-RT is a feasible and effective treatment for recurrent high-grade glioma. The significant prognostic impact of residual tumor volume highlights the importance of combining maximum-safe resection with re-RT for improved outcomes.
引用
- Mansoorian S, Schmidt M, Weissmann T, et al. Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume. J Neurooncol. 2025. PMID: 40310485. doi:10.1007/s11060-025-05042-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。